Nanoparticle vaccines

Details Nanoparticle vaccines Nanoparticle vaccines

2007-10-23

2007-10-23

Minnifield, Nita (Department: 1645)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Liposomes

C424S009321, C424S009322, C424S009340, C424S009510, C424S001210, C424S400000, C424S490000, C424S417000, C424S184100, C424S234100, C424S204100, C424S278100, C424S206100, C424S225100, C424S272100, C424S254100, C424S229100, C424S246100, C424S227100, C424S253100

Reexamination Certificate

active

10413607

ABSTRACT:
The present invention relates to nanoparticle vaccines comprised of a carrier, particularly polymerized lipids, having multiple copies of an antigen or combinations of different antigens displayed on the carrier. Such antigen-displaying nanoparticles may also display a targeting molecule on its surface in order to direct it to a specific site or cell type to optimize a desired immune response. The present invention also relates to encapsulating an antigen or combinations of different antigens within such nanoparticles, with or without a targeting molecule displayed on its surface. The antigens used in this invention are effective to produce an immune response against a variety of pathological conditions.

REFERENCES:
patent: 5512294 (1996-04-01), Li et al.
patent: 5580563 (1996-12-01), Tam
patent: 5686113 (1997-11-01), Speaker et al.
patent: 5709879 (1998-01-01), Barchfeld et al.
patent: 5762904 (1998-06-01), Okada et al.
patent: 5962422 (1999-10-01), Nagy et al.
patent: 5985852 (1999-11-01), Nagy et al.
patent: 6001395 (1999-12-01), Coombes et al.
patent: 6004534 (1999-12-01), Langer et al.
patent: 6060064 (2000-05-01), Adams et al.
patent: 6060082 (2000-05-01), Chen et al.
patent: 6086881 (2000-07-01), Frey et al.
patent: 6090406 (2000-07-01), Popescu et al.
patent: 6132764 (2000-10-01), Li et al.
patent: 6225445 (2001-05-01), Shen et al.
patent: 6235309 (2001-05-01), Nagy et al.
patent: 6299897 (2001-10-01), Nagy et al.
patent: 6326021 (2001-12-01), Schwendeman et al.
patent: 6342226 (2002-01-01), Betbeder et al.
patent: 6350466 (2002-02-01), Li et al.
patent: 6387397 (2002-05-01), Chen et al.
patent: 6500453 (2002-12-01), Brey et al.
patent: 6511677 (2003-01-01), Brey et al.
patent: 6569451 (2003-05-01), Li et al.
patent: 6663886 (2003-12-01), Nagy et al.
patent: 2002/0041861 (2002-04-01), Brey et al.
patent: 2003/0082103 (2003-05-01), Wartchow et al.
patent: 2003/0223938 (2003-12-01), Nagy et al.
patent: 2004/0022840 (2004-02-01), Nagy et al.
patent: 2004/0253184 (2004-12-01), Li et al.
patent: WO95/03035 (1995-02-01), None
patent: WO99/33940 (1999-07-01), None
patent: WO99/65465 (1999-12-01), None
patent: WO 00/23955 (2000-04-01), None
patent: WO 02/100325 (2002-12-01), None
Charych et al, Chemistry and Biology, 1996, 3:113120.
Chen et al, Book of Abstracts, ACS National Mtg. Sep. 7-11, 1997 Abstract only.
Keddy et al, Abstracts of Papers, ACS National Mtg, Aug. 26-30, 2001. Abstract only.
Pan et al, langmuir, 1997, 13:1365-1367.
Walker, Vaccine, 1994, 12/5:387-400.
Bowersock et al, Advanced Drug Delivery Reviews, 1999, 38:167-194.
Kocisko et al, J. General Viorlogy, 2004, 85:2479-2483.
Spevak et al, J. Med. Chem., 1996, 39:1018-1020.
Alonso-Romanowski et al, Chemistry and Physics of Lipids, 2003, 122:191-203.
Foster et al, Advanced Drug DeliveryReviews, 2003, 57:431-450.
Barr et al, Advanced Drug Delivery Reviews, 1998, 32:247-271.
Keegan et al, Biomaterials, 2003, 24:4435-4443.
Singh et al, International J. Parasitology, 2003, 33:469-478.
O'Hagan et al, Biomolecular Engineering, 2001, 18:69-85.
Clark et al, Advanced Drug Delivery Reviews, 2001, 50:81-106.
Brayden et al, Microbes and Infection, 2001, 3:867-876.
Nishioka et al, Advanced Drug Delivery Reviews, 2001, 47:55-64.
Chen, J. Controlled Release, 2000, 67:117-128.
Engers et al, Parasitology Today, 1998, 14/2:56-64.
Medina et al, Vaccine, 2001, 19:1573-1580.
Jeong et al, J. Biotechonology, 2002, 94:255-263.
Clark et al, Vaccine, 2002, 20:208-217.
Honda et al, J. Mol. Biol., 1999, 287:293-300.
Chen et al, J. Controlled Release, 1996, 42:263-272.
Hayward et al, FEBS, 1985, 187/2:261-266.
Okada et al, Pharmaceutical Research, 1995, 12/4:576-582.
Fabani et al, J. Liposome Research, 2002, 12/1-2:13-27.
Cohen, J. Liposome Research, 1995, 5/4:813-827.
Ohno et al, Macromolecules, 1987, 20:929-933.
Alison et al, FASEB J., Dec. 2003, 17/15:2296-2298.
Chen et al, Pharmaceutical Research, 1996, 13/9:1378-1383.
Torchilin et al, Polymer Science, 1988, 30/10:2307-2312.
Patel et al, BBRC, 2001, 281:536-543.
Chen et al, Polymeric Materials Science and Engineering, 1997, 77:599-600.
Chen et al, Proceed. Intern. Symp. Control. Rel. Bioact. Mater., 1995, 22:204-205.
Sivakumar et al, Reactive and Functional Polymers, 2001, 49/3:179-187.
Freeman et al, Biochemical Society Transactions, 1987, 15/3:413-414.
Gupta et al, Vaccine, 1996, 14/3:219-255.
Ivins et al, European J. Epidemology, 1988, 4:12-19.
Welkos et al, Microbial Pathogenesis, 1988, 5/2:127-139 Abstract only.
Patel et al, BBA, 1984, 797/1:20-26 Abstract only.
Terzano et al, European J. Pharmaceutics and Biopharmaceutics, 2005, 59/1:57-62 Abstract only.
Spevak et al, J. Am. Chem., 1993, 115:1146-1147.
Vandegriff et al, Art. Cells Blood Subs. and Immob. Biotech., 1994, 22/3:849-854.
Magalhaes et al, Biotechnol. Appl. Biochem., 2001, 33:61-64.
Kesisoglou et al, Expert Opin. Drug Deliv., 2005, 2/3:451-463.
El Baraka et a,, BBA, 1996, 1280:107-114.
Discher et al, Science, 2002, 297:967-973.
Kersten et al, Expert Rev. Vaccines, 2004, 3/4:453-462.
Vastag, JAMA, 2002, 287/12:1516-1517.
Zauner et al, Biol. Chem., 2001, 382:581-596.
Flick-Smith et al, Infection and Immunity, 2002, 70/4:2022-2028.
Bramwell et al, advanced Drug Delivery Reviews, 2005, 57:1247-1265.
Reuveny et al, Infection and Immunity, 2001, 69/5:2888-2893.
Moriya et al, Vaccine, 2002, 20:789-796.
Wilson et al, Advanced Drug Delivery Reviews, 2005, 57:1392-1402.
Welkos et al, Microbial Pathogenesis, 1988, 5:127-139.
Ivins et al, Infection and Immunity, Feb. 1990, 58/2:303-308.
Iacono-Connors et al, Infection and Immunity, Jun. 1991, 59/6:1961-1965.
Girard et al, Vaccine, 2006, 24:4062-4081.
Finco et al, Vaccine, 2005, 23:1178-1188.
Ballou et al, Am. J. Trop. Med., 2004, 71/Suppl. 2:239-247.
Clark et al., “Targeting Polymerised Liposome Vaccine Carriers to Intestinal M Cells,”Vaccine20:208-217 (2002).
Brayden et al., “Microparticle Vaccine Approaches to Stimulate Mucosal Immunisation,”Microbes and Infection3:867-876 (2001).
Jeong et al., “Enhanced Adjuvantic Property of Polymerized Liposome as Compared to a Phospholipid Liposome,”Journal of Biotechnology94:255-263 (2002).
J. Kreuter, “Nanoparticles and Microparticles for Drug and Vaccine Delivery,”J. Anat. 189:503-505 (1996).
Lian et al., “Trends and Developments in Liposome Drug Delivery Systems,”Journal of Pharmaceutical Sciences, 90(6):667-680 (2001).
B. Vastag, “Despite Finding Anthrax Vaccine Useful, IOM Recommends Seeking a Better One,”JAMA287(12):1516-17 (2002).
Brennan et al., “Cowpea Mosaic Virus as a Vaccine Carrier of Heterologous Antigens,”Molecular Biotechnology17:15-26 (2001).
Guan et al., “Liposomal Formulations of Synthetic MUC1 Peptides: Effects of Encapsulation Versus Surface Display of Peptides on Immune Response,”Bioconjugate Chem. 9:451-458 (1998).
Rajananthanan et al., “Evaluation of Novel Aggregate Structures as Adjuvants: Composition, Toxicity Studies and Humoral Responses,”Vaccine17:715-730 (1999).
Zeng et al., “Highly Immunogenic and Totally Synthetic Lipopeptides as Self-Adjuvanting Immunocontraceptive Vaccines,”The Journal of Immunology169:4905-4912 (2002).
{hacek over (R)}íhová, “Immunomodulating Activities of Soluble Synthetic Polymer-Bound Drugs,”Advanced Drug Delivery Reviews54:653-674 (2002).
Sadler et al., “Synthetic Peptide Epitope-Based Polymers: Controlling Size and Determining the Efficiency of Epitope Incorporation,”J. Peptide Res. 60:150-158 (2002).
Huang et al., “Lipophilic Multiple Antigen Peptide System for Peptide Immunogen and Synthetic Vaccine,”Molecular Immunology31(15):1191-1199 (1994).
Zeng et al., “Totally Synthetic Lipid-Containing Polyoxime Peptide Constructs are Potent Immunogens,”Vaccine18:1031-1039 (2000).
Chikh et al., “Attaching Histidine-Tagged Peptides and Proteins to Lipid-Based Carriers Through Use of Metal-Ion-Chelating Lipids,”Biochimica et Biophysica Acta1567:204-212 (2002).
Alonso-Romanowski e

Affiliated with

Also associated with

Rating

Nanoparticle vaccines does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Nanoparticle vaccines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nanoparticle vaccines will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3824848